Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 2/20 | 0.57 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.57 |
| ▸ | LMNA | P02545 | 3/20 | 0.53 |
| ▸ | NPC1 | O15118 | 2/20 | 0.51 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.51 |
| ▸ | MAPT | P10636 | 4/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.49 |
| ▸ | HPGD | P15428 | 3/20 | 0.49 |
| ▸ | HTT | P42858 | 3/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.49 |
| ▸ | RAB9A | P51151 | 1/20 | 0.49 |
| ▸ | APOBEC3A | P31941 | 1/20 | 0.49 |
| ▸ | APOBEC3G | Q9HC16 | 1/20 | 0.49 |
| ▸ | PTPN6 | P29350 | 1/20 | 0.49 |
| ▸ | PTPN11 | Q06124 | 1/20 | 0.49 |
| ▸ | PKM | P14618 | 1/20 | 0.47 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15528643 | 0.85 | F2 (0.61) | MEN1KMT2AL3MBTL1MAPTALDH1A1 | |
| SCHEMBL15529588 | 0.78 | MAPT (0.49) | MEN1KMT2ALMNANPC1MAPT | |
| SCHEMBL1528408 | 0.76 | KMT2A (0.52) | MEN1KMT2ALMNAL3MBTL1MAPT | |
| SCHEMBL1528709 | 0.76 | MAPT (0.62) | MEN1KMT2ANPC1L3MBTL1MAPT | |
| SCHEMBL1528458 | 0.73 | MAPT (0.58) | MEN1KMT2ANPC1L3MBTL1MAPT | |
| SCHEMBL1528579 | 0.72 | MAPT (0.62) | MEN1KMT2ALMNANPC1L3MBTL1 | |
| SCHEMBL15529378 | 0.71 | CYP1A2 (0.41) | KMT2ANPC1MAPTRAB9A | |
| SCHEMBL15630734 | 0.70 | POLB (0.49) | MEN1KMT2ALMNAL3MBTL1MAPT | |
| SCHEMBL6268106 | 0.69 | CYP1A2 (0.56) | NPC1MAPTHPGDSMN1; SMN2RAB9A | |
| SCHEMBL22639996 | 0.68 | MPO (0.60) | MEN1KMT2ANPC1L3MBTL1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2850068-B1 | N-(phenyl)-2-[[3-(phenyl)-1H-1,2,4-triazol-5-yl]thio]-acetamide derivatives and related compounds as G protein coupled receptor 17 (GPCR17) modulators for use in the treatment of neuro-degenerative diseases | UNIV DEGLI STUDI MILANO (IT) | 2019-05-29 | — | — | EP | claimed |
| US-9879030-B2 | GPR17 receptor modulators | UNIVERSITA′ DEGLI STUDI DI MILANO (IT) | 2018-01-30 | — | — | US | claimed |
| US-20150141410-A1 | GPR17 Receptor Modulators | UNIVERSITA' DEGLI STUDI DI MILANO (IT) | 2015-05-21 | — | — | US | claimed |
| EP-2850068-A1 | GPR17 RECEPTOR MODULATORS. | Universita' degli Studi di Milano (IT) | 2015-03-25 | — | — | EP | claimed |
| WO-2013167177-A1 | GPR17 RECEPTOR MODULATORS. | UNIVERSITA' DEGLI STUDI DI MILANO (IT) | 2013-11-14 | — | — | WO | claimed |
| EP-2850068-B1 | N-(phenyl)-2-[[3-(phenyl)-1H-1,2,4-triazol-5-yl]thio]-acetamide derivatives and related compounds as G protein coupled receptor 17 (GPCR17) modulators for use in the treatment of neuro-degenerative diseases | UNIV DEGLI STUDI MILANO (IT) | 2019-05-29 | — | — | EP | disclosed |
| US-9879030-B2 | GPR17 receptor modulators | UNIVERSITA′ DEGLI STUDI DI MILANO (IT) | 2018-01-30 | — | — | US | disclosed |
| US-20150141410-A1 | GPR17 Receptor Modulators | UNIVERSITA' DEGLI STUDI DI MILANO (IT) | 2015-05-21 | — | — | US | disclosed |
| EP-2850068-A1 | GPR17 RECEPTOR MODULATORS. | Universita' degli Studi di Milano (IT) | 2015-03-25 | — | — | EP | disclosed |
| WO-2013167177-A1 | GPR17 RECEPTOR MODULATORS. | UNIVERSITA' DEGLI STUDI DI MILANO (IT) | 2013-11-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150141410-A1 | GPR17 Receptor Modulators | GPR65, GPR27, GPR17 | MEN1 4343/4885KMT2A 3467/4885LMNA 4409/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.